

**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7)
Recombinant Antibody
Catalog # APR10914****Specification**

Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	O75084
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Additional Information**Target/Specificity**
FZD7**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Protein Information****Name** FZD7**Function**
Receptor for Wnt proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. Activation by WNT8 induces expression of beta-catenin target genes (By similarity). Following ligand activation, binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to inhibition of canonical Wnt signaling, activation of G-proteins by CCDC88C and triggering of non-canonical Wnt responses (PubMed:26126266). May be involved in transduction and intercellular transmission of polarity information during tissue

morphogenesis and/or in differentiated tissues.

Cellular Location

Cell membrane; Multi-pass membrane protein. Endosome membrane; Multi-pass membrane protein. Note=Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2). Localized in recycling endosomes in other conditions

Tissue Location


High expression in adult skeletal muscle and fetal kidney, followed by fetal lung, adult heart, brain, and placenta Specifically expressed in squamous cell esophageal carcinomas

Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) - Images



Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) is more than 95%, determined by SEC-HPLC.